Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines
Antiphospholipid antibody syndrome (APS) requires long-term anticoagulation to prevent recurrent thrombosis. Direct oral anticoagulants (DOACs) have been increasingly used in APS patients, but contradictory guidelines recommendations on their use do exist. We performed a systematic review of literat...
Main Authors: | Daniele Pastori, Danilo Menichelli, Vittoria Cammisotto, Pasquale Pignatelli |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.715878/full |
Similar Items
-
Direct-acting oral anticoagulants in antiphospholipid syndrome
by: T. M. Reshetnyak, et al.
Published: (2021-01-01) -
Direct-acting oral anticoagulants: An overview
by: Hatem H Salem
Published: (2017-01-01) -
Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
by: Gilda Denise Zielinski, et al.
Published: (2020-01-01) -
Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists
by: Martin Müller, et al.
Published: (2019-04-01) -
Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older
by: Patrick Manckoundia, et al.
Published: (2021-04-01)